ANPI

Overview

Highlights

News

Chart

Contacts

 

   
 
   
"Intellectual property includes over 150 issued U.S. patents and 185 pending U.S. patent applications. The  combined global company has over 1,500 employees worldwide.  
   
   
Approximate Financial Snapshot as of 10/10/07
Shares Outstanding 85.01M
52 Wk Hi/Lo 9.81/

5.28

Market Cap $567M
Recent Price $6.67

 

 

Join the SmallCapReview mailing list
Email:

 

10/10/07

Angiotech Pharmaceuticals (ANPI)

Website: www.angiotech.com

Redefining Success


Overview

Angiotech Pharmaceuticals (ANPI) operates as a specialty pharmaceutical and medical device company. It discovers, develops, and markets technologies and medical products for local diseases and complications associated with medical device implants, surgical interventions, and acute injury. 

ANPI offers various technologies that improve the performance of medical devices and the outcomes of surgical procedures. These technologies include various drug, drug delivery, and surface modification materials and other medical biomaterials designed to be applied across a range of medical devices and technologies, surgical procedures, and medical disciplines. 

Angiotech also manufactures and markets single use, specialty medical devices, with products focused primarily on general surgery; oncology and tumor biopsy; interventional radiology and vascular surgery; ophthalmology; and aesthetic surgery.

Its product candidates that are undergoing human clinical trials include TAXUS Liberte paclitaxel-eluting coronary stent system, which is related to the use of paclitaxel to prevent restenosis and other local inflammatory diseases; ZILVER PTX paclitaxel-eluting peripheral vascular stent that is designed for placement in diseased arteries in the limbs to restore blood flow; Vascular Wrap, a paclitaxel-eluting mesh surgical implant designed to treat complications associated with vascular graft implants in patients undergoing hemodialysis or have peripheral artery disease; and Anti-Infective Catheter related to central venous catheters. 

Angiotech has license agreements with Boston Scientific Corporation, Cook Group Incorporated, and a distribution and license agreement with Orthovita Inc. The Company also has a  manufacturing and supply agreement with Baxter Healthcare Corporation; a collaboration agreement with Genzyme Corporation and CombinatoRx Inc, and a strategic alliance agreement with Athersys Inc. 

Intellectual property includes over 150 issued U.S. patents and 185 pending U.S. patent applications. The  combined global company has over 1,500 employees worldwide.

This is an abbreviated profile and we encourage readers interested in learning more about Angiotech Pharmaceuticals to visit the company website at www.angiotech.com.


ANPI Investor Highlights

  • Announced that it intends to file Premarket Notification 510(k) documents with the U.S. Food and Drug Administration (FDA) for its innovative, anti-infective 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC).
  • Announced that it has received FDA and CE Mark approval to begin marketing additional diameters of its Quill Self-Retaining System Polydioxanone product line in the U.S. and Europe.
  • Announced that it reached a favorable agreement with Johnson & Johnson's subsidiary, Conor Medsystems to settle all outstanding patent litigation with respect to Conor's CoStar paclitaxel stent.
  • Announced that the U.S. Food and Drug Administration (FDA) has given clearance to begin marketing the Hemo-Stream chronic dialysis catheter.
  • Total revenue for the 2nd quarter as adjusted for non-recurring items, was $75.3 million. Total revenue under generally accepted accounting principles ("GAAP") was $72.4 million.

Recent News and Press Releases

Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line

Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial

Angiotech announces further European expansion of the Quill(TM) SRS PDO product line

Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation

Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office

Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance

Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Angiotech reports second quarter results

For the latest Quote and News on ANPI Click Here.


Three Month Chart


 


Contacts

Angiotech Pharmaceuticals
1618 Station Street
Vancouver, BC V6A 1B6
Canada
Phone: 604-221-7676
Fax: 604-221-2330


SEC Filings

ANPI filings with the SEC can be found here. All Fillings are current and the Company is fully reporting.


Disclaimer

SmallCapReview.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of ANPI, please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), SmallCapReview.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview.com web site. SmallCapReview.com has not been compensated for its efforts in presenting the Angiotech Pharmaceuticals profile on its website and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.